-
21.发明申请公开(公告)号：US20200300870A1
公开(公告)日：2020-09-24
申请号：US16753295
申请日：2018-10-02
Inventor： Jae Young SEONG , Byung Joo HAM , Min-Hyeok LEE , Nui HA
IPC: G01N33/68 , C12Q1/6883
Abstract: The present disclosure relates to a method of diagnosing a mood disorder in a subject comprising measuring serum FAM19A5 concentration with an antagonist (e.g., an antibody or antigen-binding fragment thereof) that specifically binds to FAM19A5. The present disclosure also relates to a method of treating a mood disorder in a subject in need thereof comprising administering to the subject an FAM19A5 antagonist.
-
公开(公告)号：US20200270337A1
公开(公告)日：2020-08-27
申请号：US16807902
申请日：2020-03-03
Applicant: Neuracle Science Co., Ltd.
Inventor： Jae Young SEONG , Jong Ik HWANG , Woong SUN , Eun Bee CHO , Won-Ki KIM
IPC: C07K16/24 , C07K14/47 , C12Q1/6886 , A61K38/17 , A61K48/00 , C07K16/18 , C12N15/113 , G01N33/577 , G01N33/68
Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
-
公开(公告)号：US20170121401A1
公开(公告)日：2017-05-04
申请号：US15404011
申请日：2017-01-11
Applicant: Neuracle Science Co., Ltd.
Inventor： Jae Young SEONG , Jong Ik Hwang , Woong Sun , Eun Bee Cho , Won-Ki Kim
IPC: C07K16/24 , G01N33/577 , G01N33/68
CPC classification number: C07K16/24 , A61K38/1709 , A61K48/00 , A61K2039/505 , C07K14/4701 , C07K14/4702 , C07K16/18 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/76 , C12N15/113 , C12N2310/11 , C12N2310/141 , C12Q1/6886 , C12Q2600/156 , G01N33/577 , G01N33/6896 , G01N2333/47
Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
-
公开(公告)号：US20240238445A1
公开(公告)日：2024-07-18
申请号：US18552290
申请日：2022-07-08
Applicant: NEURACLE SCIENCE CO., LTD. , KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION , KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SEJONG CAMPUS
Inventor： Jae Young SEONG , Youngjoo BYUN , Hoyun KWAK , Sitaek OH , Min-Hyeok LEE , Yongwoo JEONG , Nui HA , Eun-Ho CHO , Suhyun LEE , Sang-Myeong LEE , Yerim LEE , Eun Bee CHO , Jae Keun LEE , Han-Byul KIM , Soon-gu KWON
IPC: A61K48/00 , A61K31/055 , A61K31/085 , A61K31/136 , A61K31/137 , A61K38/08 , A61K38/10 , A61K38/17 , A61K45/06 , A61K47/64 , A61P25/02 , A61P25/28 , C12N5/0793
CPC classification number: A61K48/005 , A61K31/055 , A61K31/085 , A61K31/136 , A61K31/137 , A61K38/08 , A61K38/10 , A61K38/1709 , A61K45/06 , A61K47/64 , A61P25/02 , A61P25/28 , C12N5/0619
Abstract: The present disclosure provides mimic molecules that are capable of specifically targeting a FAM19A5 protein, and thereby, inhibiting, reducing, and/or dissociating the interaction between members of the LRRC4 protein family and the FAM19A5 protein. The present disclosure also provides methods for promoting neurite outgrowth, by administering a mimic molecule described herein.
-
公开(公告)号：US20230348584A1
公开(公告)日：2023-11-02
申请号：US18158259
申请日：2023-01-23
Applicant: Neuracle Science Co., Ltd.
Inventor： Bongcheol KIM , Eun Bee CHO , Dong Sik KIM , Jae-Keun LEE , Soon-gu KWON , Jae Young SEONG , Juwon SHIM , Tae Woo KIM , Shin-hyuk KANG
Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.
-
Patent Agency Ranking
公开(公告)号：US11739141B2
公开(公告)日：2023-08-29
申请号：US16807902
申请日：2020-03-03
Applicant: Neuracle Science Co., Ltd.
Inventor： Jae Young Seong , Jong Ik Hwang , Woong Sun , Eun Bee Cho , Won-Ki Kim
IPC: C07K16/24 , C12Q1/6886 , C07K16/18 , G01N33/577 , G01N33/68 , A61K39/00 , C07K14/47 , A61K38/17 , A61K48/00 , C12N15/113
CPC classification number: C07K16/24 , A61K38/1709 , A61K48/00 , C07K14/4701 , C07K14/4702 , C07K16/18 , C12N15/113 , C12Q1/6886 , G01N33/577 , G01N33/6896 , A61K2039/505 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/76 , C12N2310/11 , C12N2310/141 , C12Q2600/156 , G01N2333/47
Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
-
公开(公告)号：US20220064277A1
公开(公告)日：2022-03-03
申请号：US17418681
申请日：2019-12-26
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Bongcheol KIM , Dong Sik KIM , Jae-Keun LEE , Juwon SHIM
Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat an atherosclerosis in a subject in need thereof.
-
公开(公告)号：US20200299373A1
公开(公告)日：2020-09-24
申请号：US16626624
申请日：2018-06-27
Inventor： Bongcheol KIM , Jae-Keun LEE , Dong Sik KIM , Junho CHUNG , Junyeong JIN
IPC: C07K16/24 , A61P35/00 , G01N33/574 , G01N33/50
Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Also provided herein are methods for treating fibrosis or cancer using the anti-FAM19A5 antibodies.
-
29.发明申请公开(公告)号：US20190300599A1
公开(公告)日：2019-10-03
申请号：US16348058
申请日：2017-11-07
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Bongcheol KIM , Jae Young SEONG , Jong Ik HWANG , Eun Bee CHO , Junho CHUNG , Junyeong JIN , Tae Young YUNE , Jee Youn LEE
IPC: C07K16/18 , G01N33/563
Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.
-
公开(公告)号：US10385098B2
公开(公告)日：2019-08-20
申请号：US15771078
申请日：2016-11-30
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Jae Young Seong , Jong-Ik Hwang , Dong-Hoon Kim , Gi Hoon Son , Yoo-Na Lee , Seongsik Yun , Arfaxad Reyes-Alcaraz
IPC: C07K7/08 , A61K38/00 , A61K9/19 , A61K9/00 , A61P25/06 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30
Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.
-
-
-
-
-
-
-
-
-
Search Results
42
records
(took 0.018 seconds)
